← Leaderboards
Shizhen Zhu
Mayo Clinic Rochester
$2,778,196
Attributed
$2,778,196
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $363.7K · FY2013–24$500K$375K$250K$125K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,778,196 · 3
By mechanism
R01$1,785,830 · 1
R00$747,000 · 1
K99$245,366 · 1
Top collaborators
No co-investigators on record.
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Cornelia M Weyand$30,789,284
- Cheryl A Conover$8,047,873
- Jorg J Goronzy$24,125,737
Others in their field
Top investigators on “Tissues”
- David Heimbrook · Leidos Biomedical Research, Inc.$346,311,904
- Lawrence Corey · Fred Hutchinson Cancer Center$230,011,824
- Larry Arthur$159,140,370
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Judith S. Currier · University Of California Los Angeles$138,805,403
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$138,805,403
Research focus
TissuesTreatment FailureGenomicsSignal TransductionSuccessPathogenesisChildhoodGenesMutationMycn GeneNeuroblastomaNeoplastic CellOncogenesOverexpressionChemotherapyBiologyCoupledDoxycyclineHigh RiskMalignant NeoplasmsMemberMolecular TargetCessation Of LifeTumor
Grant awards (10)
Interplay between low levels of GAS7 expression and MYCN overexpression and its impact on neuroblastoma metastasis$345,528
R01 · FY2024 · CA · contact PI
Interplay between low levels of GAS7 expression and MYCN overexpression and its impact on neuroblastoma metastasis$356,438
R01 · FY2023 · CA · contact PI
Interplay between low levels of GAS7 expression and MYCN overexpression and its impact on neuroblastoma metastasis$356,438
R01 · FY2022 · CA · contact PI
Interplay between low levels of GAS7 expression and MYCN overexpression and its impact on neuroblastoma metastasis$363,713
R01 · FY2021 · CA · contact PI
Interplay between low levels of GAS7 expression and MYCN overexpression and its impact on neuroblastoma metastasis$363,713
R01 · FY2020 · CA · contact PI
Pathogenic Roles of SHP2 & PTPRD Tyrosine Phosphatases in High-Risk Neuroblastoma$249,000
R00 · FY2017 · CA · contact PI
Pathogenic Roles of SHP2 & PTPRD Tyrosine Phosphatases in High-Risk Neuroblastoma$249,000
R00 · FY2016 · CA · contact PI
Pathogenic Roles of SHP2 & PTPRD Tyrosine Phosphatases in High-Risk Neuroblastoma$249,000
R00 · FY2015 · CA · contact PI
Pathogenic Roles of SHP2 & PTPRD Tyrosine Phosphatases in High-Risk Neuroblastoma$122,683
K99 · FY2014 · CA · contact PI
Pathogenic Roles of SHP2 & PTPRD Tyrosine Phosphatases in High-Risk Neuroblastoma$122,683
K99 · FY2013 · CA · contact PI